Hangzhou Highlightll Pharmaceutical Co., Ltd
Clinical trials sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New arthritis drug TLL-018 moves to Long-Term safety check in 350 patients Results expected Dec 2026 (estimated)
- New eczema ointment shows promise in early trial Results expected Jun 2027 (estimated)
- Can a new pill tame rheumatoid arthritis when standard drugs fail? Results expected Jul 2027 (estimated)
-
New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial
Disease control CompletedThis phase 2 trial tests whether an experimental oral drug called TLL018 can improve skin clearance in adults with moderate-to-severe plaque psoriasis. Participants receive one of two doses of TLL018 or a placebo for 12 weeks. The main goal is to see if at least 75% of skin plaqu…
Phase 2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New eczema ointment takes first step in human safety trial
Symptom relief CompletedThis early-stage trial tests whether HL-300 ointment is safe and tolerable when applied to the skin of healthy adult volunteers. Researchers will give single or multiple doses of the ointment or a placebo to 36 participants aged 18 to 45 in China. The study monitors for side effe…
Phase 1 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC